Previous Close | 4.7000 |
Open | 4.7000 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 4.7000 - 4.7000 |
52 Week Range | 4.7000 - 4.7000 |
Volume | |
Avg. Volume | 0 |
Market Cap | 309.281M |
Beta (5Y Monthly) | 0.31 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.5500 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for BOVNF
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced preliminary encouraging efficacy data for BI-1206 in combination with rituximab in patients
LUND, SWEDEN / ACCESSWIRE / February 22, 2024 / BioInvent International (STO:BINV) "2023 was a landmark year for BioInvent with positive clinical readouts from three Phase 1/2 programs. These data, supported by validating partnerships, a strong cash ...
LUND, SE / ACCESSWIRE / February 20, 2024 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the year-end report 2023 at 2:00 pm on February 22. The report will be published ...